title: Chemotherapy for hormone-resistant prostate cancer: Where are we today?
abstract: Significant progress has been achieved in chemotherapy for hormone-resistant prostate cancer (HRPC) in the last five years. Although the disease was long considered to be chemoresistant, docetaxel-based regimens in particular have been shown to both palliate symptoms and prolong survival in HRPC patients. Docetaxel is now considered the best available chemotherapy for prostate cancer progressing on first-line hormonal treatment. Other cytotoxics including mitoxantrone, anthracyclines, vinorelbin and vinblastine can alleviate symptoms and improve progression-free survival in HRPC without affecting overall survival. The survival benefit from chemotherapy seen in randomized studies has been small or nonexistent. Results of a recent trial suggest that the survival benefit may have been underestimated as a result of crossover from the less active to the active arm.
authors.affiliation: Department of Oncology, University College London Hospital, London, United Kingdom.
authors.forename: Tomas
authors.initials: T
authors.lastname: Buchler
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Harland
references.citation: Br J Cancer. 2004 Oct 18;91(8):1472-6
references.pmid: 15381936
references.citation: Oncologist. 2002;7(4):360-70
references.pmid: 12185298
references.citation: Oncology. 2005;68(1):2-9
references.pmid: 15741753
references.citation: Eur Urol. 2003 Nov;44(5):519-26
references.pmid: 14572748
references.citation: J Clin Oncol. 1996 May;14(5):1617-25
references.pmid: 8622080
references.citation: Am J Clin Oncol. 2004 Dec;27(6):550-4
references.pmid: 15577431
references.citation: N Engl J Med. 2004 Oct 7;351(15):1513-20
references.pmid: 15470214
references.citation: Prostate. 1992;20(1):43-50
references.pmid: 1736276
references.citation: Urology. 2005 May;65(5 Suppl):3-7; discussion 7-8
references.pmid: 15885271
references.citation: Clin Cancer Res. 1997 Dec;3(12 Pt 1):2371-6
references.pmid: 9815636
references.citation: J Clin Oncol. 1999 Nov;17(11):3461-7
references.pmid: 10550143
references.citation: Urology. 2004 May;63(5):940-5
references.pmid: 15134985
references.citation: Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):805-13
references.pmid: 8478230
references.citation: J Clin Oncol. 2005 May 20;23(15):3343-51
references.pmid: 15738542
references.citation: J Clin Oncol. 2001 Mar 1;19(5):1304-11
references.pmid: 11230472
references.citation: Cancer. 2006 Mar 1;106(5):1041-6
references.pmid: 16456811
references.citation: J Natl Cancer Inst. 2006 Apr 19;98(8):516-21
references.pmid: 16622120
references.citation: J Urol. 2002 Dec;168(6):2439-43
references.pmid: 12441935
references.citation: J Clin Oncol. 2005 Nov 10;23(32):8247-52
references.pmid: 16278480
references.citation: J Clin Oncol. 1999 Aug;17(8):2506-13
references.pmid: 10561316
references.citation: Eur J Cancer. 1997 Apr;33(4):566-74
references.pmid: 9274436
references.citation: Oncologist. 2005;10 Suppl 3:30-9
references.pmid: 16368869
references.citation: J Clin Oncol. 1999 Mar;17(3):958-67
references.pmid: 10071290
references.citation: Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):699-703
references.pmid: 11172951
references.citation: Semin Oncol. 1999 Oct;26(5 Suppl 17):39-44
references.pmid: 10604268
references.citation: Semin Oncol. 1999 Oct;26(5 Suppl 17):28-33
references.pmid: 10604266
references.citation: N Engl J Med. 2004 Oct 7;351(15):1502-12
references.pmid: 15470213
references.citation: Eur Urol. 1997;31(1):7-10
references.pmid: 9032527
references.citation: J Clin Oncol. 1999 Oct;17(10):3160-6
references.pmid: 10506613
references.citation: J Clin Oncol. 2005 Nov 10;23(32):8253-61
references.pmid: 16278481
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2828-35
references.pmid: 16782921
references.citation: Ann Oncol. 1999 Jan;10(1):33-8
references.pmid: 10076719
references.citation: Urology. 2006 Jun;67(6):1235-40
references.pmid: 16765185
references.citation: J Clin Oncol. 2001 May 1;19(9):2509-16
references.pmid: 11331330
references.citation: J Clin Oncol. 1996 Jun;14(6):1756-64
references.pmid: 8656243
references.citation: Ann Oncol. 2004 Nov;15(11):1613-21
references.pmid: 15520061
references.citation: Urology. 1992 Jun;39(6):577-82
references.pmid: 1615614